Overview

Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder

Status:
RECRUITING
Trial end date:
2027-02-28
Target enrollment:
Participant gender:
Summary
A placebo-controlled superiority design was used to evaluate the efficacy of 40 mg/ day of Crisugabalin capsules in the treatment of GAD.
Phase:
PHASE2
Details
Lead Sponsor:
Anhui Medical University
Treatments:
BID protein, human
tebufenozide